We are further advancing our technologies!
Please see Tubulis’ recent publication in Molecular Cancer Therapeutics on how to leverage the unique properties of our P5 technology to generate cutting-edge Topo-I-based high DAR ADCs with minimal aggregation, mAb like PK of the ADC and highest linkage stability leading to unrivaled in vivo efficacy.
